PMCB
PharmaCyte Biotech, Inc.
Key Financials
Operating Income
$-4377862
↑ 48.6%
Net Income
$30.7M
↑ 9085.0%
Gross Profit
$0
NaN%
EPS (Diluted)
$3.19
↑ 277.2%
Total Liabilities
$3.3M
↓ 83.9%
Total Assets
$55.2M
↓ 7.9%
Shareholders' Equity
$51.9M
↑ 87.7%
Cash & Equivalents
$15.2M
↓ 69.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| SCHEDULE 13G | 3/18/2026 | View on SEC |
| 10-Q | 3/17/2026 | View on SEC |
| ARS | 3/9/2026 | View on SEC |
| DEF 14A | 3/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PMCB |
| Company Name | PharmaCyte Biotech, Inc. |
| CIK | 1157075 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0430 |
| State of Incorporation | NV |
| Phone | (917) 595.2850 |